These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24132302)

  • 41. Synthesis and characterization of homo- and heteronuclear molecular Al3+ and Th4+ species chelated by the ethylenediaminetetraacetate (edta) ligand.
    Fairley M; Unruh DK; Donovan A; Abeysinghe S; Forbes TZ
    Dalton Trans; 2013 Oct; 42(37):13706-14. PubMed ID: 23904037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 1H and 17O NMR relaxometric study in aqueous solution of Gd(III) complexes of EGTA-like derivatives bearing methylenephosphonic groups.
    Tei L; Botta M; Lovazzano C; Barge A; Milone L; Aime S
    Magn Reson Chem; 2008; 46 Suppl 1():S86-93. PubMed ID: 18855344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Coordination studies of Al-EDTA in aqueous solution.
    Coskuner O; Jarvis EA
    J Phys Chem A; 2008 Mar; 112(12):2628-33. PubMed ID: 18293948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NSF after Gadovist exposure: a case report and hypothesis of NSF development.
    Wollanka H; Weidenmaier W; Giersig C
    Nephrol Dial Transplant; 2009 Dec; 24(12):3882-4. PubMed ID: 19767635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.
    Adiseshaiah P; Dellinger A; MacFarland D; Stern S; Dobrovolskaia M; Ileva L; Patri AK; Bernardo M; Brooks DB; Zhou Z; McNeil S; Kepley C
    Invest Radiol; 2013 Nov; 48(11):745-54. PubMed ID: 23748228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of a ditopic Gd(III) paramagnetic probe for investigating α-bungarotoxin surface accessibility.
    Bernini A; Spiga O; Venditti V; Prischi F; Botta M; Croce G; Tong AP; Wong WT; Niccolai N
    J Inorg Biochem; 2012 Jul; 112():25-31. PubMed ID: 22542593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
    Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
    Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
    Sanyal S; Marckmann P; Scherer S; Abraham JL
    Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unexpected aggregation of neutral, xylene-cored dinuclear GdIII chelates in aqueous solution.
    Costa J; Balogh E; Turcry V; Tripier R; Le Baccon M; Chuburu F; Handel H; Helm L; Tóth E; Merbach AE
    Chemistry; 2006 Sep; 12(26):6841-51. PubMed ID: 16770815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Extracellular gadolinium contrast agents: differences in stability.
    Morcos SK
    Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm.
    Perazella MA
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):519-25. PubMed ID: 19623065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of clonal T cells in the circulation of patients with nephrogenic systemic fibrosis.
    Kreuter A; Höxtermann S; Gambichler T; Tigges C; Hahn SA; Schieren G
    Arch Dermatol; 2009 Oct; 145(10):1164-9. PubMed ID: 19841405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Nephrogenic systemic fibrosis--new clinical entity].
    Prvulović M
    Med Pregl; 2008; 61(9-10):439-41. PubMed ID: 19203058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of ligand scaffold size on the stability of tripodal hydroxypyridonate gadolinium complexes.
    O'Sullivan B; Doble DM; Thompson MK; Siering C; Xu J; Botta M; Aime S; Raymond KN
    Inorg Chem; 2003 Apr; 42(8):2577-83. PubMed ID: 12691564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents.
    Tóth E; Bolskar RD; Borel A; González G; Helm L; Merbach AE; Sitharaman B; Wilson LJ
    J Am Chem Soc; 2005 Jan; 127(2):799-805. PubMed ID: 15643906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Carbonate and phosphite encaged in frameworks constructed from square lanthanum aminopolycarboxylates and sodium chloride.
    Wang SY; Gao S; Dai JW; Shi YR; Dong X; Weng WZ; Zhou ZH
    Dalton Trans; 2019 Feb; 48(9):2959-2966. PubMed ID: 30741287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of the operating magnetic field on potential NMR contrast agents.
    Brown MA
    Magn Reson Imaging; 1985; 3(1):3-10. PubMed ID: 3923291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-Argininium phosphite - a new candidate for NLO materials.
    Ghazaryan VV; Zakharov BA; Petrosyan AM; Boldyreva EV
    Acta Crystallogr C Struct Chem; 2015 May; 71(Pt 5):415-21. PubMed ID: 25940900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.